옵션 체인은 다양한 행사가격과 만기일에 대한 Owens & Minor의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Owens & Minor에 대한 시장 심리를 평가합니다..

Owens & Minor (NYSE:OMI) 주식, 옵션 체인

Owens & Minor

Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CNN 공포·탐욕 지수는 전반적인 시장 감정에서 개선을 보였지만, 월요일(3일)에는 여전히 &#34;공포&#34; 영역에 머물렀다.

멕시코·캐나다 관세 유예 이후 다우 지수 하락폭 축소: 탐욕 지수는 &#39;공포&#39; 영역

Owens & Minor Inc

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Systems Inc

Omid Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

OmiseGO - United States Dollar

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $15 to $14.

Price Target

Analyst Ratings

Baird Maintains Neutral on Owens & Minor, Lowers Price Target to $14

U.S. stock futures were trading lower on Tuesday after Monday&#8217;s decline as the new administration&#8217;s tariffs continued to spook the market.
On Monday, Mexico&#8217;s president Claudia Sheinbaum reached a deal with President Donald Trump to delay tariffs by increasing Mexico's military presence on the US border. Later, after a call between Trump and Canadian Prime Minister Justin Trudeau, tariffs on Canada were also suspended for 30 days.
All major index futures were down. Google parent Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) and Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) are expected to report earnings today.
The 10-year Treasury yield stood at 4.58%, while the two-year yield was at 4.25%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is an 86.5% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.10%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.20%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.14%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) were mixed during premarket trading on Tuesday. SPY fell 0.17% to $596.75, and QQQ was up 0.01% to $518.16, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
US stocks <a href="https://www.benzinga.com/25/02/43455955/dow-trims-losses-after-trump-delays-mexico-tariff-investor-sentiment-improves-fear-greed-index-in-fear-zone">declined</a> on Monday following Trump&#8217;s tariff announcement which led to the Dow dropping over 665 points intraday. 
Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares fell 35% after lowering revenue guidance, while Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) reported strong earnings.
December U.S. construction spending rose 0.5%, and the January ISM manufacturing PMI increased to 50.9.
Most S&amp;P 500 sectors declined, led by consumer discretionary, information technology, and industrials, while utilities and consumer staples gained.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-1.20%</td>
<td>19,391.96</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.76%</td>
<td>5,994.57</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.28%</td>
<td>44,421.91</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.28%</td>
<td>2,258.42</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
As the market declined following the tariffs and trade wars, Ryan Detrick, the chief market strategist at Carson Research, calmed the investors down by highlighting that every year has scary headlines that pull the stock market down.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Every year has scary headlines. <a href="https://t.co/1JknCIqrRc">pic.twitter.com/1JknCIqrRc</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1886424284609835091?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He further explained the basic principle of investing in the market by saying &#8220;Volatility is the toll we pay to invest&#8221;.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Now&#39;s a good time to remember that volatility is the toll we pay to invest. Each year has scary moments, it is all part of investing. <a href="https://t.co/9FezMYHa4M">pic.twitter.com/9FezMYHa4M</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1886424165021819285?ref_src=twsrc%5Etfw">February 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Highlighting the tariff impact, economist Jeremy Siegel said that the prospect of new trade barriers introduces another layer of volatility, with markets reacting negatively to the uncertainty.
&#8220;History has shown that tariffs are rarely viewed as a net positive for equities, and while they could lead to a temporary bump in inflation and price levels, the Fed is unlikely to respond to a one-time inflationary shock,&#8221; he added.
While Mexican and Canadian tariffs were paused, Siegel, who is the senior economist at WisdomTree and a former professor at the University of Pennsylvania added that &#8220;Trump's new tariffs are not smart either economically or politically&#8221;.
&#8220;The political impact is likely to be very negative for Trump's program, as the rise in prices (gasoline and some food items) will have high visibility in the mainstream media and put pressure on some legislators,&#8221; he added.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul>
<li>December&#8217;s job openings and factory orders data will be out at 10:00 a.m., ET</li>
</ul>
<ul>
<li>Atlanta Fed President Raphael Bostic will speak again at 11:00 a.m., ET on Tuesday, on the topic of housing.</li>
</ul>
<ul>
<li>San Francisco Fed President Daly will speak at 2:00 p.m., ET and Federal Reserve Vice Chairman Philip Jefferson will speak at 7:30 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) was up 2.90% in the premarket on Tuesday as it is expected to report its fourth-quarter earnings before the market opens. According to Benzinga's consensus estimates, the company is expected to report earnings of $2.060 per share on the revenue of $4.15 billion.</li>
</ul>
<ul>
<li>PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) declined 0.19% ahead of its earnings before the opening bell. Analysts expect it to report quarterly earnings of $1.94 per share on revenue of $27.89 billion.</li>
</ul>
<ul>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) rose 0.53% as Wall Street expects it to report quarterly earnings of 47 cents per share on revenue of $17.40 billion.</li>
</ul>
<ul>
<li>Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) slipped 0.19% ahead of its earnings which will be released after the closing bell. Analysts expect it to report quarterly earnings of $3.08 per share on revenue of $2.32 billion.</li>
</ul>
<ul>
<li>UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>) fell 5.58% despite reporting stronger-than-expected earnings for its fourth quarter because it disclosed a share buyback program of up to $3 billion, which failed to impress investors.</li>
</ul>
<ul>
<li>NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) was up 0.80% as it posted upbeat earnings and sales results for its fourth quarter on Monday.</li>
</ul>
<ul>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) was up 18.77% following better-than-expected fourth-quarter results.</li>
</ul>
<ul>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) slipped 5.11% and PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) declined 3.98% as the Chinese Ministry of Commerce added the companies to the unreliable entities list amid the ongoing trade war with the U.S.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.54% to hover around $72.03 per barrel.
The gold spot index was down by 0.01% to $2,814.48 per ounce. The Dollar Index was down 0.36% at 108.60 level.
Asian markets were mixed on Tuesday as China's CSI 300 and Australia's ASX 200 index fell. Whereas Hong Kong's Hang Seng, South Korea's Kospi, and Japan's Nikkei 225 index advanced. European markets were also mixed in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/sector-etfs/25/02/43456454/bill-gates-says-nvidias-jensen-huang-could-be-wrong-about-quantum-computing-qubt-rgti-ionq-react-in-tuesday-premarket">Bill Gates Says Nvidia&#8217;s Jensen Huang &#8216;Could Be Wrong&#8217; About Quantum Computing: QUBT, RGTI, IONQ React In Tuesday Premarket </a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Government

Futures

Politics

Economics

GOOG

GOOGL

ILMN

NXPI

PLTR

SPOT

US Stocks Likely To Open Lower As Trump's Trade War Continues To Impact The Market: 'Volatility Is The Toll We Pay To Invest,' Says Expert

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Monday.
U.S. stocks settled lower on Monday, with the Dow Jones index falling more than 100 points during the session after President Donald Trump announced plans to pause tariffs against Mexico for one month. The index dipped as much as 665.6 points earlier during the session.
Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dipped 35% on Monday after the company issued lower-than-expected fourth-quarter and FY24 preliminary revenue results. Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) posted better-than-expected first-quarter FY25 earnings results.
On the economic data front, U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November. The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December topping estimates of 49.8.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, information technology, and industrials stocks recording losses on Monday. However, utilities and consumer staples stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 123 points to 44,421.91 on Monday. The S&amp;P 500 fell 0.76% to 5,994.57, while the Nasdaq Composite fell 1.20% at 19,391.96 during Monday's session.
Investors are awaiting earnings results from Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 44.1, the index remained in the &#8220;Fear&#8221; zone on Monday, versus a prior reading of 40.5.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432950/jim-cramer-appfolio-is-a-cheap-stock-dont-sell-this-tech-stock">Jim Cramer Says AppFolio Is A &#8216;Good One,&#8217; But Summit Therapeutics? &#8216;Can&#8217;t Go There&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Dow Trims Losses After Trump Delays Mexico, Canada Tariffs: Greed Index Remains In 'Fear' Zone

Owens & Minor Shares Resume Trade Following Circuit Breaker Halt

U.S. stocks traded lower toward the end of trading, with the S&amp;P 500 falling around 0.5% on Monday.
The Dow traded down 0.09% to 44,506.60 while the NASDAQ dipped 0.91% to 19,449.55. The S&amp;P 500 also fell, dropping, 0.53% to 6,008.22.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Consumer staples shares surged by 0.7% on Monday.
In trading on Monday, information technology shares fell by 1.4%.
Top Headline
U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 131% to $0.6431 after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>Shares of Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>)got a boost, surging 34% to $25.14 after the company agreed to go private in a $3 billion deal backed by Warburg Pincus and Berkshire Partners.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares were also up, gaining 81% to $19.17 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dropped 32% to $9.68 after the company issued lower-than-expected fourth-quarter and FY24 preliminary revenue results.</li>
<li>Shares of Napco Security Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) were down 29% to $26.11 following second-quarter results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) was down, falling 55% to $0.1941. Tonix Pharmaceuticals announced a 1-for-100 reverse stock split, effective Feb. 5.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $72.95 while gold traded up 0.8% at $2,857.30.
Silver traded up 0.8% to $32.530 on Monday, while copper rose 1% to $4.3195.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.87%, Germany's DAX 40 dipped 1.40% and France's CAC 40 declined 1.20%. Spain's IBEX 35 Index fell 1.32%, while London's FTSE 100 fell 1.04%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 2.66%, Hong Kong's Hang Seng Index fell 0.04% and India's BSE Sensex falling 0.41%.
Economics
<ul>
<li>U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.</li>
<li>The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.</li>
<li>The S&amp;P Global manufacturing PMI rose to 51.2 in January, versus a preliminary reading of 50.1 and compared to 49.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432854/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q4 Earnings</a></li>
</ul>

Eurozone

Commodities

Intraday Update

GHRS

HCWB

NSSC

TNXP

Crude Oil Moves Higher; Owens & Minor Shares Plummet

U.S. stocks traded lower midway through trading, with the Dow Jones index falling around 150 points on Monday.
The Dow traded down 0.33% to 44,398.37 while the NASDAQ dipped 1.36% to 19,360.28. The S&amp;P 500 also fell, dropping, 0.89% to 5,986.91.
Check This Out: <a href="https://www.benzinga.com/25/01/43388778/jim-cramer-autozone-is-a-great-stock-recommends-buying-this-energy-stock">Jim Cramer: AutoZone Is A &#8216;Great&#8217; Stock, Recommends Buying This Energy Stock</a>
Leading and Lagging Sectors Health care shares surged by 0.3% on Monday.
In trading on Monday, information technology shares fell by 1.7%.
Top Headline
The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 112% to $0.59 after the company announced FDA clearance for its Phase 1 trial of HCW9302.</li>
<li>Shares of Triumph Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>)got a boost, surging 34% to $25.19 after the company agreed to go private in a $3 billion deal backed by Warburg Pincus and Berkshire Partners.</li>
<li>GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares were also up, gaining 82% to $19.25 after the company&#8217;s inhalable depression treatment GH001 met the primary endpoint in its Phase 2b trial, showing symptom reduction.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dropped 25% to $10.67 after the company issued lower-than-expected fourth-quarter and FY24 preliminary revenue results.</li>
<li>Shares of Napco Security Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) were down 25% to $27.70 following second-quarter results.</li>
<li>Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) was down, falling 49% to $0.2184. Tonix Pharmaceuticals announced a 1-for-100 reverse stock split, effective Feb. 5.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $72.49 while gold traded up 0.7% at $2,853.30.
Silver traded down 0.4% to $32.150 on Monday, while copper fell 0.1% to $4.2755.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.83%, Germany's DAX 40 dipped 1.38% and France's CAC 40 declined 1.08%. Spain's IBEX 35 Index fell 1.32%, while London's FTSE 100 fell 1.04%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 2.66%, Hong Kong's Hang Seng Index fell 0.04% and India's BSE Sensex falling 0.41%.
Economics
<ul>
<li>U.S. construction spending increased by 0.5% month-over-month to an annual rate of $2,192 billion in December following a revised 0.2% gain in November.</li>
<li>The ISM manufacturing PMI for the US climbed to 50.9 in January versus a revised reading of 49.2 in December and topping estimates of 49.8.</li>
<li>The S&amp;P Global manufacturing PMI rose to 51.2 in January, versus a preliminary reading of 50.1 and compared to 49.4 in December.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43432854/how-to-earn-500-a-month-from-pepsico-stock-ahead-of-q4-earnings">How To Earn $500 A Month From PepsiCo Stock Ahead Of Q4 Earnings</a></li>
</ul>

Dow Falls 150 Points; ISM Manufacturing PMI Rises In January

WIIM

Owens & Minor shares are trading lower after the company issued lower-than-expected Q4 and FY24 preliminary revenue results.

Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dipped premarket on Monday after the company disclosed preliminary results and financing for the previously announced <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43429536/owens-minor-launches-financing-for-rotech-acquisition-and-provides-preliminary-fourth-quarter-and-" rel="noreferrer noopener">Rotech Healthcare Holdings, Inc</a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43429536/owens-minor-launches-financing-for-rotech-acquisition-and-provides-preliminary-fourth-quarter-and-" rel="noreferrer noopener">. buyout</a>.
Edward A. Pesicka, President &amp; Chief Executive Officer of Owens &amp; Minor, said, &#8220;We are commencing a process to raise additional debt while the capital markets are attractive, to finance our previously announced agreement to acquire Rotech which we continue to expect will close in the first half of 2025.&#8221;
&#8221;Our healthy free cash flow provides the vehicle for this proposed financing as well as helping us achieve our deleveraging goals over the next few years.&#8221;&nbsp;
Notably, in July 2024, the company announced the acquisition of Rotech <a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39914439/healthcare-logistics-service-firm-owens-minor-to-buy-home-based-care-equipment-firm-for-1-4b-sees-b" rel="noreferrer noopener">Healthcare</a><a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39914439/healthcare-logistics-service-firm-owens-minor-to-buy-home-based-care-equipment-firm-for-1-4b-sees-b" rel="noreferrer noopener"> </a><a target="_blank" href="https://www.benzinga.com/news/earnings/24/07/39914439/healthcare-logistics-service-firm-owens-minor-to-buy-home-based-care-equipment-firm-for-1-4b-sees-b" rel="noreferrer noopener">for $1.36 billion in cash</a>.
Preliminary Results: For the fourth quarter, Owens &amp; Minor sees revenue of&nbsp;$2.67 billion – $2.70 billion (vs. consensus of&nbsp;$2.731 billion) and adjusted EPS&nbsp;of $0.52 –$0.55&nbsp;(compared<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> to the street view of&nbsp;$0.53)</a>.
For 2024, the company stated preliminary revenue of $10.67 billion &#8211; $10.70 billion (vs. $10.736 billion estimate) and adjusted EPS of $1.50 &#8211; $1.53 (vs. consensus of $1.51).
The company expects to witness a non-cash goodwill impairment charge of around $310 million within its Apria division, or a net loss of about $4.00 per share.
This reflects financial market changes in the fourth quarter of 2024, which include a decline in Owens &amp; Minor&#8217;s stock price, rising interest rates, and anticipated pricing changes in a capitated contract.
Pesicka added, &#8220;We are particularly excited about the full-year performance of our Patient Direct segment which posted solid mid-single digit growth, and even higher in key categories.&#8221;
&#8221;In addition, we are pleased that in a year of meaningful reinvestment in the business we were able to reduce total debt by over $240 million.&#8221;
The company plans to report its fourth-quarter and full-year 2024 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">financial results on February 28, 2025</a>.
Investors can gain exposure to the stock via&nbsp;Invesco Exchange-Traded Fund Trust II Invesco S&amp;P SmallCap 600 Revenue ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RWJ#NYSE">RWJ</a>).
Price Action: OMI shares are down 8.71% at $13.00 premarket at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43429067" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Lower As Trump Imposes Tariffs On China, Canada, And Mexico: Expert Notes Feb Worst Month In Post-Election Years</a></li>
</ul>
Image via Shutterstock.

Mid Cap

Guidance

Movers

Owens & Minor Stock Dips On Mixed Q4 Preliminary Results & $310 Million Apria Goodwill Charge: Details

Preliminary Full Year 2024 Results Including Non-Cash Goodwill Impairment (i):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Revenue of $10.67 – $10.70 billion</li>
</ul>
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Net loss of $(378) – $(355) million</li>
</ul>
</td>
<td colspan="1" rowspan="1">
<ul>
<li>Adjusted EBITDA of $520 – $525 million</li>
</ul>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Net loss per share $(4.92) – $(4.63)</li>
</ul>
</td>
<td colspan="1" rowspan="1">
<ul>
<li>Adjusted EPS of $1.50 – $1.53</li>
</ul>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Gross capital expenditures of $228 – $233 million</li>
</ul>
</td>
<td colspan="1" rowspan="1">
<ul>
<li>Capital expenditures, net of PSE regular sales proceeds, of $158 – $163 million</li>
</ul>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Total debt of $1.854 – $1.859 billion</li>
</ul>
</td>
<td colspan="1" rowspan="1">
<ul>
<li>Net debt of $1.805 – $1.810 billion</li>
</ul>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Cash provided by operating activities of $160 – $165 million</li>
</ul>
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">(i)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Reconciliations of the differences between the non-GAAP financial measures in this release and their most directly comparable GAAP financial measures are included in the tables below.</td>
</tr>
</tbody>
</table>
</figure>

Owens & Minor Reports 2024 Preliminary Revenue Of $10.67B–$10.70B (Vs. $10.736B Est.) And Adj. EPS $1.50-$1.53 (Vs. $1.51 Est.)

Preliminary Fourth Quarter 2024 Results Including Non-Cash Goodwill Impairment (i):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Revenue of $2.67 – $2.70 billion</li>
</ul>
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Net loss of $(311) – $(288) million</li>
</ul>
</td>
<td colspan="1" rowspan="1">
<ul>
<li>Adjusted EBITDA of $135 – $140 million</li>
</ul>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Net loss per share $(4.03) – $(3.73)</li>
</ul>
</td>
<td colspan="1" rowspan="1">
<ul>
<li>Adjusted EPS of $0.52 – $0.55</li>
</ul>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Gross capital expenditures of $71 – $76 million</li>
</ul>
</td>
<td colspan="1" rowspan="1">
<ul>
<li>Capital Expenditures, net of patient service equipment (PSE) regular sales proceeds, of $53 – $58 million</li>
</ul>
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
<ul>
<li>Cash provided by operating activities of $70 – $75 million</li>
</ul>
</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Owens & Minor Launches Financing For Rotech Acquisition, Reports Q4 Preliminary Revenue Of $2.67B–$2.70B (Vs. $2.731B Est.) And Adj. EPS $0.52–$0.55 (Vs. $0.53 Est.)

<a href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owens-minor-inc-dba-american-contract-systems-inc-695683-11012024" title="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owens-minor-inc-dba-american-contract-systems-inc-695683-11012024">https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/owens-minor-inc-dba-american-contract-systems-inc-695683-11012024</a>

FDA Issues Warning Letter To Owens & Minor Over Serious Quality Control And Compliance Failures In Sterile Medical Device Manufacturing, Requires Corrective Actions Within 15 Days

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $17.9, along with a high estimate of $25.00 and a low estimate of $14.00. This current average represents a 17.13% decrease from the previous average price target of $21.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1730836906_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Owens &amp; Minor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$18.50</td>
<td>$21.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$22.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Owens &amp; Minor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Owens &amp; Minor compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Owens &amp; Minor's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Owens &amp; Minor's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OMI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Owens &amp; Minor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Owens &amp; Minor's Background</h2>
Owens &amp; Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products &amp; Healthcare Services and Patient Direct. The Products &amp; Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products &amp; Healthcare Services segment.
<h3>Financial Milestones: Owens &amp; Minor's Journey</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Owens &amp; Minor showcased positive performance, achieving a revenue growth rate of 4.2% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Owens &amp; Minor's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.64%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Owens &amp; Minor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.61%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 2.77, Owens &amp; Minor faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Owens & Minor

UBS analyst Kevin Caliendo maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $28 to $25.

UBS Maintains Buy on Owens & Minor, Lowers Price Target to $25

Citigroup analyst Daniel Grosslight maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $21 to $18.5.

Citigroup Maintains Buy on Owens & Minor, Lowers Price Target to $18.5

Barclays analyst Steven Valiquette maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Equal-Weight and lowers the price target from $18 to $14.

Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $14

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity raised Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) price target from $24 to $28. Canaccord Genuity analyst Maria Ripps maintained a Buy rating. Hims &amp; Hers Health shares closed at $20.76 on Monday. See how other analysts view this stock.</li>
<li>Benchmark raised the price target for Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) from $440 to $450. Benchmark analyst Matthew Harrigan maintained a Buy rating. Charter Communications shares closed at $375.83 on Monday. <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut the price target for Celanese Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) from $165 to $115. Wells Fargo analyst Michael Sison downgraded the stock from Overweight to Equal-Weight. Celanese shares closed at $123.50 on Monday. <a href="https://www.benzinga.com/quote/CE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group slashed Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) price target from $95 to $75. Telsey Advisory Group analyst Joseph Feldman downgraded the stock from Outperform to Market Perform. Dollar Tree shares settled at $66.81 on Monday. <a href="https://www.benzinga.com/quote/DLTR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna slashed Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) price target from $65 to $55. Susquehanna analyst Christopher Rolland maintained a Positive rating. Lattice Semiconductor shares closed at $51.89 on Monday. <a href="https://www.benzinga.com/quote/LSCC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut Navitas Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) price target from $7 to $5. Baird analyst Tristan Gerra maintained an Outperform rating. Navitas Semiconductor shares closed at $2.61 on Monday. <a href="https://www.benzinga.com/quote/NVTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital increased the price target for Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) from $22 to $22.5. Loop Capital analyst Rick Paterson downgraded the stock from Buy to Hold. Air Transport shares settled at $22.00 on Monday. <a href="https://www.benzinga.com/quote/ATSG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) price target from $19 to $14. Baird analyst Eric Coldwell maintained a Neutral rating. Owens &amp; Minor shares closed at $12.00 on Monday. <a href="https://www.benzinga.com/quote/OMI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel boosted the price target for Alkermes plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) from $25 to $36. Stifel analyst Paul Matteis upgraded the stock from Hold to Buy. Alkermes shares closed at $26.59 on Monday. <a href="https://www.benzinga.com/quote/ALKS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted MasTec, Inc.. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) price target from $133 to $173. Truist Securities analyst Jamie Cook upgraded the stock from Hold to Buy. MasTec shares closed at $132.61 on Monday. <a href="https://www.benzinga.com/quote/MTZ/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

ALKS

ATSG

CHTR

DLTR

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LSCC

NVTS

Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and lowers the price target from $19 to $14.

Owens & Minor shares are trading higher after the company reported better-than-expected Q3 financial results and raised the lower end of its FY24 guidance.

On Monday,&nbsp;Owens &amp; Minor Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported the third quarter of 2024 adjusted EPS of $0.42, down from $0.44 reported a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.41</a>.
The company reported sales of $2.72 billion, up 5% year-over-year, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41708956/owens-minor-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $2.68 billion</a>.
Patient Direct revenue of $687 million, up 6% year-over-year, driven by strength in several categories led by diabetes and sleep supplies.
Products &amp; Healthcare Services revenue of $2.0 billion, up 5%, driven primarily by strong same-store sales in the Medical Distribution division and one additional sales day.
Third quarter 2024 operating income of $24 million and adjusted operating income of $84 million. Adjusted EBITDA increased 5% to $142 million.
"Our third quarter results demonstrated our ability to deliver on our commitments both near-term as well as on our strategic initiatives. Our Patient Direct segment continues to perform well in the growing home-based care space while we continue investing to support long-term profitable growth. In our Products &amp; Healthcare Services segment, we continue to see solid top-line results, especially within our Medical Distribution division supported by recent wins and deepened relationships with our existing customers," said Edward A. Pesicka, President &amp; Chief Executive Officer of Owens &amp; Minor.
Guidance:&nbsp;Owens &amp; Minor see full-year 2024 revenue of $10.6 billion-$10.8 billion compared to the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40130112/healthcare-logistics-provider-owens-minor-calls-q2-performance-consistent-with-expectations-reitera" rel="noreferrer noopener">prior guidance of</a> $10.5 billion-$10.9 billion and consensus of $10.713 billion.
The healthcare logistics&nbsp;company expects 2024 adjusted EPS of $1.45-$1.55, compared to prior guidance of $1.40-$1.70 and the consensus of $1.60.
Pesicka concluded, "Looking ahead, we are confident in our ability to show good sequential growth and cash flow from the third to fourth quarter, which positions us well as we enter 2025. Each of the segments should benefit from seasonality and investments of the last several quarters as we finish 2024 and look to the future."
Price Action:&nbsp;OMI stock is down 8.27% at $12.26 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41710271/roaring-kitty-stock-chewy-set-to-join-s-p-midcap-400-index-will-replace-stericycle" target="_blank" rel="noreferrer noopener">Roaring Kitty Stock Chewy Set to Join S&amp;P MidCap 400 Index, Will Replace Stericycle</a></li>
</ul>

Health Care

General

Health Solutions Provider Owens & Minor's Q3 Earnings: Revenue And EPS Beat, Trims Annual Outlook

Owens & Minor Expects 2024 Adjusted EPS Of $1.45-$1.55  Compared To Prior Guidance Of $1.40-$1.70, Versus Consensus Of $1.60

"We are commencing a process to raise additional debt while the capital markets are attractive, to finance our previously announced agreement to ac...

Owens & Minor commences process to raise additional debt

Sees Q4 revenue $2.67B-$2.7V, consensus $2.73B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial new...

Owens & Minor sees Q4 adjusted EPS 52c-55c, consensus 53c

Sees FY24 revenue $10.67B-$10.7B, consensus $10.74B. Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

Owens & Minor sees FY24 adjusted EPS $1.50-$1.53, consensus $1.51

Owens & Minor (OMI) is down -14.3%, or -$2.04 to $12.21. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Owens & Minor falls -14.3%

Owens & Minor (OMI) is down -27.4%, or -$3.90 to $10.34. Published first on TheFly – the ultimate source for real-time, market-moving breaking fina...

Owens & Minor falls -27.4%

Stocks are lower midday, but have pared much steeper premarket losses, after U.S. President Trump paused tariffs on Mexico for one month.

Stocks Pare Losses After Trump Pauses Mexico Tariffs

15:36 EST Owens & Minor (OMI) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news....

Owens & Minor trading resumes

15:30 EST Owens & Minor (OMI) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving...

Owens & Minor trading halted, volatility trading pause

Owens & Minor falls 35% on goodwill impairment charge, taking on new debt

Baird lowered the firm's price target on Owens & Minor to $14 from $15 and keeps a Neutral rating on the shares. The firm said its preliminary Q4 r...

Owens & Minor price target lowered to $14 from $15 at Baird

TEAM

Small Cap

Press Releases

OMI Investors Have Opportunity to Join Owens & Minor, Inc. Fraud Investigation with the Schall Law Firm

Legal

Bragar Eagel & Squire, P.C. Is Investigating Helen of Troy, Owens & Minor, Salesforce, and Phreesia and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Is Investigating Helen of Troy, Owens & Minor, Iris Energy, and DexCom and Encourages Investors to Contact the Firm

Owens & Minor to Present at the 2024 Baird Global Healthcare Conference

Owens & Minor Announces New Partnership with Google Cloud

Owens & Minor Names Jonathan Leon Executive Vice President, Chief Financial Officer

Owens & Minor Announces Third Quarter 2024 Earnings Release Date and Conference Call

Owens & Minor Reports Third Quarter 2024 Financial Results

Owens & Minor to Present at Upcoming Investor Conferences

Owens & Minor Launches Financing for Rotech Acquisition and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Results Ahead of Investor Meetings

Comments

Owens & Minor

Owens & Minor (OMI) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌